Browsing Tag
immuno-oncology
35 posts
Mural Oncology shareholders to receive fixed $2.035 per share as XOMA Royalty deal nears closing
Mural Oncology confirms a fixed $2.035 per share cash payout as its acquisition by XOMA Royalty nears closing, locking in a definitive exit for investors.
Investors eye PHIO as Phio Pharmaceuticals reports full Phase 1b enrollment and strong preliminary PH-762 results
Find out how Phio Pharmaceuticals’ PH-762 trial progress and early response signals could reshape RNA-based cancer therapies.
Can immunotherapy finally replace chemo in bladder cancer? Keytruda–Padcev combo shows the way
Explore how Merck’s Keytruda and Padcev combo is redefining bladder cancer treatment without chemo. Survival gains, sector impact, and what’s next in focus.
Metastatic TNBC sees unexpected remission as Kazia Therapeutics’ Q4 update reveals pipeline momentum across cancer programs
Learn how Kazia Therapeutics’ rare iCR in metastatic TNBC is reshaping its breast cancer, immuno-oncology, and GBM pipeline strategy.
Caribou Biosciences set for key webcast showcasing CRISPR-engineered CAR-T breakthroughs in blood cancers
Discover how Caribou Biosciences is preparing to reveal breakthrough CRISPR-edited allogeneic CAR-T data in lymphoma and myeloma during its investor webcast.
First patient dosed in Adagene’s Phase 2 study of Muzastotug (ADG126) with KEYTRUDA for microsatellite stable colorectal cancer
Find out how Adagene’s Muzastotug and KEYTRUDA combination could redefine immunotherapy for microsatellite stable colorectal cancer.
How Purple Biotech’s CAPTN-3 platform achieved a tri-specific antibody manufacturing milestone with IM1240
Find out how Purple Biotech’s manufacturing milestone for IM1240 is validating the CAPTN-3 platform and transforming tri-specific antibody development.
RNAZ stock surges as TransCode Therapeutics buys Polynoma and wins $25m CK Life Sciences funding for metastatic cancer pipeline
Find out how TransCode Therapeutics’ $25M CK Life Sciences funding and Polynoma buyout could redefine RNAZ’s role in cancer immunotherapy.
HanchorBio and Henlius sign $202m licensing deal for HCB101 to expand immuno-oncology access across Asia and MENA
HanchorBio Inc. (7827.TWO), a clinical-stage immunotherapy innovator, has entered a major licensing agreement with Shanghai Henlius Biotech Inc.…
Dr Reddy’s launches toripalimab in India as first immuno-oncology drug for nasopharyngeal carcinoma
Dr. Reddy’s Laboratories Ltd. announced a significant milestone in its oncology portfolio with the launch of Toripalimab in…